How long should I take Midostaurin during treatment?

Midostaurin (Midostaurin), as an oral multi-target kinase inhibitor, has been used in the treatment of FLT3 mutation-positive acute myeloid leukemia (AML) in recent years, as well as in the treatment of late-stage acute myeloid leukemia (AML). It has shown significant efficacy in various stages of systemic mastocytosis (SM), including aggressive systemic mastocytosis (ASM), systemic mastocytosis with hematological neoplasm (SM-AHN), and mast cell leukemia (MCL). However, many patients and family members have questions about the duration of midostaurin treatment. This question will be answered in detail below.

For AML patients, midostaurin is often used in combination with chemotherapy drugs. Patients take 50 mg of midostaurin twice daily on days 8 to 21 of each chemotherapy cycle (usually 21 days). This combination treatment regimen typically lasts for multiple cycles, with the exact number of cycles based on the patient's specific condition and physician recommendations. However, it is worth noting that midostaurin will not be used indefinitely for a long time, and the treatment duration will generally be adjusted based on the patient's response and tolerance.

Forpatients with ASM, SM-AHN, and MCL, the recommended dose of midostaurin is 100 mg twice daily. Treatment continues until disease progression or the patient experiences unacceptable toxicity. This means that, unlike the treatment of AML, the duration of midostaurin treatment for ASM patients may be more flexible and more dependent on the patient's individual response.

Regardless of the disease, the duration of midostaurin treatment is not set in stone. The doctor will make a comprehensive judgment based on the patient's specific situation, such as disease severity, physical tolerance, treatment response and other factors. At the same time, regular monitoring and evaluation are essential to ensure the effectiveness and safety of treatment.

During the period of taking midostaurin, patients should strictly follow the doctor's instructions and are not allowed to adjust the dosage or stop the medication on their own. In addition, since midostaurin may cause certain side effects, such as nausea, vomiting, etc., patients should pay close attention to their physical condition during treatment and report any discomfort to their doctor in a timely manner.

To sum up, the treatment duration of midostaurin varies depending on the condition and individual differences, and requires doctors and patients to work together to adjust and optimize according to the specific situation. Midostaurin is currently sold overseas. A box of the original Indian version costs more than RMB 3,000, while a box of the Indian generic version of the same specification costs more than RMB 2,000. Patients should choose by themselves.